NASDAQ:IDXX - IDEXX Laboratories Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $628.86
  • Forecasted Upside: 75.44 %
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$358.44
▲ +7.71 (2.20%)

This chart shows the closing price for IDXX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New IDEXX Laboratories Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IDXX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IDXX

Analyst Price Target is $628.86
▲ +75.44% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for IDEXX Laboratories in the last 3 months. The average price target is $628.86, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 75.44% upside from the last price of $358.44.

This chart shows the closing price for IDXX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 9 polled investment analysts is to buy stock in IDEXX Laboratories. This rating has held steady since August 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/11/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/11/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/10/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/8/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/6/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/6/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/5/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/5/2022

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/24/2022Stifel NicolausLower Price TargetBuy$575.00 ➝ $500.00Low
5/19/2022The Goldman Sachs GroupLower Price TargetNeutral$615.00 ➝ $530.00Low
5/5/2022Bank of AmericaDowngradeBuy ➝ Neutral$550.00 ➝ $470.00High
2/8/2022Atlantic SecuritiesInitiated CoverageOverweight$650.00Low
2/2/2022William BlairReiterated RatingOutperformLow
11/18/2021Morgan StanleyInitiated CoverageOverweight$732.00Medium
8/13/2021Credit Suisse GroupBoost Price TargetOutperform$735.00 ➝ $770.00Low
8/5/2021Credit Suisse GroupInitiated CoverageOutperform$735.00Medium
8/3/2021The Goldman Sachs GroupBoost Price TargetNeutral$550.00 ➝ $610.00Medium
8/2/2021BarclaysBoost Price TargetOverweight$616.00 ➝ $750.00Low
7/12/2021GuggenheimDowngradeBuy ➝ NeutralMedium
5/5/2021BarclaysBoost Price TargetOverweight$600.00 ➝ $616.00Low
2/17/2021BarclaysInitiated CoverageOverweight$600.00Low
1/29/2021JPMorgan Chase & Co.Initiated CoverageOverweight$570.00Low
8/17/2020Credit Suisse GroupBoost Price TargetOutperform$415.00 ➝ $422.00Low
8/4/2020Credit Suisse GroupBoost Price TargetOutperform$300.00 ➝ $415.00Low
7/30/2020Stifel NicolausBoost Price TargetBuy$280.00 ➝ $375.00Low
7/20/2020Bank of AmericaBoost Price TargetBuy$300.00 ➝ $390.00Medium
5/1/2020Stifel NicolausBoost Price TargetBuy$266.00 ➝ $280.00Medium
11/1/2019GuggenheimSet Price TargetBuy$310.00Low
9/9/2019The Goldman Sachs GroupInitiated CoverageNeutral$277.00High
8/16/2019Credit Suisse GroupBoost Price TargetOutperform$282.00 ➝ $293.00Low
7/22/2019Stifel NicolausBoost Price TargetBuy$255.00 ➝ $295.00Low
6/21/2019Bank of AmericaSet Price TargetBuy$300.00Low
5/23/2019GuggenheimInitiated CoverageBuy ➝ Buy$276.00Medium
11/2/2018Bank of AmericaLower Price TargetBuy ➝ Buy$275.00 ➝ $235.00Low
8/17/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$255.00 ➝ $259.00Low
8/1/2018Piper Jaffray CompaniesBoost Price TargetOverweight$236.00Medium
7/10/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$225.00 ➝ $260.00High
6/21/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$228.00 ➝ $231.00Low
6/1/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$209.00 ➝ $228.00High
5/7/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$215.00 ➝ $225.00High
2/2/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$200.00 ➝ $220.00High
2/1/2018Piper Jaffray CompaniesBoost Price TargetOverweight$211.00High
1/16/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$200.00High
12/8/2017AegisReiterated RatingSellLow
10/24/2017Stifel NicolausReiterated RatingBuy$185.00N/A
8/23/2017Bank of AmericaUpgradeNeutral ➝ Buy$175.00Low
8/21/2017Stifel NicolausReiterated RatingBuy$185.00Low
8/2/2017Stifel NicolausReiterated RatingBuy$185.00High
7/28/2017CL KingUpgradeNeutral ➝ Buy$200.00Medium
7/14/2017Stifel NicolausReiterated RatingBuy$185.00Low
(Data available from 7/5/2017 forward)

News Sentiment Rating

0.46 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/7/2021
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/6/2022
  • 5 very positive mentions
  • 18 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
2/5/2022
  • 2 very positive mentions
  • 23 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
3/7/2022
  • 9 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
4/6/2022
  • 2 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
5/6/2022
  • 3 very positive mentions
  • 27 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
6/5/2022
  • 3 very positive mentions
  • 3 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
7/5/2022

Current Sentiment

  • 3 very positive mentions
  • 3 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
IDEXX Laboratories logo
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Read More

Today's Range

Now: $358.44
Low: $348.59
High: $359.23

50 Day Range

MA: $369.79
Low: $327.37
High: $455.56

52 Week Range

Now: $358.44
Low: $318.50
High: $706.95

Volume

14,019 shs

Average Volume

618,847 shs

Market Capitalization

$30.11 billion

P/E Ratio

42.02

Dividend Yield

N/A

Beta

1.12

Frequently Asked Questions

What sell-side analysts currently cover shares of IDEXX Laboratories?

The following Wall Street research analysts have issued reports on IDEXX Laboratories in the last year: Atlantic Securities, Bank of America Co., Barclays PLC, Credit Suisse Group AG, Guggenheim, Morgan Stanley, Stifel Nicolaus, StockNews.com, The Goldman Sachs Group, Inc., TheStreet, and William Blair.
View the latest analyst ratings for IDXX.

What is the current price target for IDEXX Laboratories?

0 Wall Street analysts have set twelve-month price targets for IDEXX Laboratories in the last year. Their average twelve-month price target is $628.86, suggesting a possible upside of 75.4%.
View the latest price targets for IDXX.

What is the current consensus analyst rating for IDEXX Laboratories?

IDEXX Laboratories currently has 3 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IDXX will outperform the market and that investors should add to their positions of IDEXX Laboratories.
View the latest ratings for IDXX.

How do I contact IDEXX Laboratories' investor relations team?

IDEXX Laboratories' physical mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company's listed phone number is (207) 556-0300 and its investor relations email address is [email protected] The official website for IDEXX Laboratories is www.idexx.com. Learn More about contacing IDEXX Laboratories investor relations.